全文获取类型
收费全文 | 2931篇 |
免费 | 200篇 |
国内免费 | 149篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 114篇 |
妇产科学 | 14篇 |
基础医学 | 240篇 |
口腔科学 | 39篇 |
临床医学 | 597篇 |
内科学 | 641篇 |
皮肤病学 | 34篇 |
神经病学 | 416篇 |
特种医学 | 406篇 |
外科学 | 130篇 |
综合类 | 52篇 |
预防医学 | 112篇 |
眼科学 | 31篇 |
药学 | 194篇 |
1篇 | |
肿瘤学 | 252篇 |
出版年
2023年 | 19篇 |
2021年 | 41篇 |
2020年 | 27篇 |
2019年 | 30篇 |
2018年 | 41篇 |
2017年 | 30篇 |
2016年 | 36篇 |
2015年 | 34篇 |
2014年 | 35篇 |
2013年 | 75篇 |
2012年 | 60篇 |
2011年 | 101篇 |
2010年 | 82篇 |
2009年 | 80篇 |
2008年 | 125篇 |
2007年 | 206篇 |
2006年 | 96篇 |
2005年 | 116篇 |
2004年 | 98篇 |
2003年 | 108篇 |
2002年 | 95篇 |
2001年 | 79篇 |
2000年 | 69篇 |
1999年 | 74篇 |
1998年 | 88篇 |
1997年 | 90篇 |
1996年 | 90篇 |
1995年 | 76篇 |
1994年 | 52篇 |
1993年 | 66篇 |
1992年 | 58篇 |
1991年 | 65篇 |
1990年 | 56篇 |
1989年 | 87篇 |
1988年 | 67篇 |
1987年 | 88篇 |
1986年 | 56篇 |
1985年 | 74篇 |
1984年 | 53篇 |
1983年 | 50篇 |
1982年 | 40篇 |
1981年 | 35篇 |
1980年 | 33篇 |
1979年 | 29篇 |
1978年 | 34篇 |
1977年 | 37篇 |
1976年 | 43篇 |
1975年 | 27篇 |
1974年 | 19篇 |
1971年 | 21篇 |
排序方式: 共有3280条查询结果,搜索用时 15 毫秒
51.
Global profiling of Shewanella oneidensis MR-1: expression of hypothetical genes and improved functional annotations 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kolker E Picone AF Galperin MY Romine MF Higdon R Makarova KS Kolker N Anderson GA Qiu X Auberry KJ Babnigg G Beliaev AS Edlefsen P Elias DA Gorby YA Holzman T Klappenbach JA Konstantinidis KT Land ML Lipton MS McCue LA Monroe M Pasa-Tolic L Pinchuk G Purvine S Serres MH Tsapin S Zakrajsek BA Zhu W Zhou J Larimer FW Lawrence CE Riley M Collart FR Yates JR Smith RD Giometti CS Nealson KH Fredrickson JK Tiedje JM 《Proceedings of the National Academy of Sciences of the United States of America》2005,102(6):2099-2104
52.
S Magura R C Freeman Q Siddiqi D S Lipton 《The International journal of the addictions》1992,27(1):51-69
Radioimmunoassay of hair (RIAH) was compared with two criterion measures, confidential EMIT urinalysis and self-reporting of cocaine/heroin use, for a purposive sample of 134 persons in methadone treatment. Positive or negative RIAH was "confirmed" by urinalysis and/or self-report in 87 and 84% of the cases for cocaine and heroin (morphine), respectively. Corroborative evidence indicated that "excess" RIAH positives were attributable to the narrow window of detection for urinalysis (2 days), failure to admit drug use even to researchers, and/or inadvertent ingestion of small amounts of drug. A global self-report of cocaine use intensity was related to amount in the hair. 相似文献
53.
54.
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind,Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab
下载免费PDF全文
![点击此处可从《Headache》网站下载免费的PDF全文](/ch/ext_images/free.gif)
David W. Ayer PhD Vladimir Skljarevski MD Janet H. Ford PhD Allen W. Nyhuis MS Richard B. Lipton MD Sheena K. Aurora MD 《Headache》2018,58(8):1225-1235
Objective – To evaluate 12‐week changes from baseline of 2 disease‐specific patient‐reported outcome (PRO) measures in adults with migraine treated with galcanezumab, an investigational humanized antibody binding calcitonin gene‐related peptide (CGRP), or placebo. Background – Preventing headache‐related functional impairment is an important goal of migraine preventive treatment and a measurement target for PROs. Understanding which drugs have the potential to improve patient functioning in addition to preventing migraine headaches is vital to lessening patient burden. Design/Methods – This Phase 2b double‐blind, randomized, placebo‐controlled study enrolled adults with episodic migraine. Galcanezumab (120 mg subcutaneous injection; n = 60) or placebo (n = 127) was administered every 28 days for 12 weeks. Post hoc secondary analyses were conducted for those who completed 12 weeks of treatment on 2 PROs: The Migraine‐Specific Quality of Life Questionnaire (MSQ) v2.1 and the Headache Impact Test? (HIT‐6). Results – Analysis of covariance revealed significant differences in least square mean changes from baseline between galcanezumab and placebo for all MSQ domains including total mean change placebo of 18.63, galcanezumab of 27.36 (95% CI 2.449, 15.008; P‐value of .0067); Role Function‐Restrictive mean change placebo of 22.40, galcanezumab of 31.92 (95% CI 2.636, 16.518; P‐value of .0071); Role Function‐Preventive mean change placebo of 13.43, galcanezumab of 19.76 (95% CI 0.476, 12.185; P‐value of .0342); and Emotional Function mean change placebo of 16.88, galcanezumab of 26.61 (95% CI 2.789, 16.674; P‐value of .0063). At baseline, mean number of migraine headache days (MHDs) did not correlate with MSQ total scores or HIT‐6. At 12 weeks post‐treatment, MHD correlated with MSQ and HIT‐6 scores (all P < .0001). Change in MHD was associated with change in MSQ domains and change in HIT‐6 scores (all P < .0001). Conclusions – In comparison with placebo, treatment with galcanezumab was associated with significant functional improvements as reflected by changes in MSQ scores. Change in MHD was associated with improvements in MSQ and reductions in HIT‐6 scores, indicating the clinical importance of these changes in relation to PROs that measure function. 相似文献
55.
Lipton RB Baggish JS Stewart WF Codispoti JR Fu M 《Archives of internal medicine》2000,160(22):3486-3492
BACKGROUND: Although most persons with migraine treat their headaches with over-the-counter medication, systematic data on the safety and efficacy of widely used treatment, including acetaminophen, are sparse. METHODS: This is a randomized, double-blind, placebo-controlled study comparing oral acetaminophen, 1000 mg (two 500-mg Extra Strength Tylenol tablets), with identical placebo in the treatment of a single acute migraine attack. Eligible subjects met International Headache Society diagnostic criteria for migraine with or without aura. Patients who usually required bed rest with their headaches or who vomited more than 20% of the time were excluded. MAIN OUTCOME MEASURES: The percentage of subjects who, at 2 hours after dosing, experienced a change in baseline pain intensity from severe or moderate pain to mild or no pain (headache response); and pain intensity difference from baseline at the 2-hour postmedication assessment. RESULTS: The headache response rate 2 hours after dosing was 57.8% in the acetaminophen group and 38.7% in the placebo group (P =.002). Pain-free rates at 2 hours were 22.4% in the acetaminophen group and 11.3% in the placebo group (P =.01). The mean pain intensity difference from baseline 2 hours after dosing was 1.08 in the acetaminophen group and 0.73 in the placebo group (P<.001). At 2 hours, other migraine headache characteristics, such as functional disability (P =.002), photophobia (P =.02), and phonophobia (P =.08), were significantly improved after treatment with acetaminophen vs placebo. CONCLUSIONS: Acetaminophen was highly effective for treating pain, functional disability, photophobia, and phonophobia in a population-based sample of persons with migraine, excluding the most disabled persons with migraine. The drug also had an excellent safety profile and was well tolerated. Arch Intern Med. 2000;160:3486-3492. 相似文献
56.
R. S. Weinberg A. Vlachos V. Najfeld Y. Galperin A. Scalise S. Fruchtman & J. M. Lipton 《British journal of haematology》1997,99(1):61-63
A 4-year-old girl with transfusion-dependent β°-thalassaemia received an HLA-identical bone marrow transplant (BMT) from her β°-thalassaemia trait sister. Prior to BMT, chromosomal analysis revealed the recipient to have 46,XX,9qh+, a polymorphic variant of the heterochromatin region of chromosome 9, which her donor did not have. Within 1 month post-BMT, 89% of nucleated bone marrow cells were of donor origin. One year later, donor engraftment had decreased to 44% and 34% in nucleated bone marrow cells and blood lymphocytes, respectively. By 2 years, donor lymphocyte engraftment fell to 5%, raising concern of possible graft rejection. To examine erythroid chimaerism, globin synthesis by individual erythroid progenitor cell derived colonies (BFU-E) was analysed. On days 1000 and 1130 post-BMT, 79% and 77% of colonies, respectively, synthesized β-globin and therefore were of donor origin. 相似文献
57.
P H Kleinman S Y Kang D S Lipton G E Woody J Kemp R B Millman 《The American journal of drug and alcohol abuse》1992,18(1):29-43
Retention in outpatient psychotherapy of 148 crack and cocaine abusers was examined. The clients were predominantly Black (63%) and Hispanic (21%), predominantly male (87%), and the majority (66%) had completed no more than 12 years of high school. Clients entered treatment in a low-cost treatment center in New York City between June 1987 and November 1988. Forty-two percent (62) of the subjects were seen for one or two research interviews only, and did not return to begin therapy. Of the 86 persons who came to at least one therapy session, 30% (26) dropped out before the third session, 28% (24) dropped out between the third and fifth sessions, and 42% (36) were retained for six or more sessions. Short-term and longer-term retentions were analyzed separately, using a battery including sociodemographic variables, treatment history, psychiatric symptomatology, number of arrests, and drug use variables. None of the variables considered was significantly related to short-term retention. There were large although not significant differences in longer term retention by therapist. Longer-term retention was associated significantly with being White (contrasted with being Black) and being young. Nonsignificant but large associations were found between longer-term retention and having few arrests, being Hispanic (contrasted with being Black), and having low SCL-90 scores. Results are compared with previous findings about retention in drug and alcohol treatment. It is suggested that future research on retention in treatment focus less on client variables and more on therapist and program variables. 相似文献
58.
Kiss TL Chang H Daly A Messner HA Jamal N Spaner D Rubin S Lipton JH 《Bone marrow transplantation》2004,33(8):855-858
Pre transplant screening work-up of donors for allogeneic blood and marrow transplantation is essential in an effort to minimize risks to the recipient and protect the donor. At Princess Margaret Hospital, every potential donor is screened with a bone marrow aspirate. The case histories of three asymptomatic potential donors who presented within 1 year with normal complete blood counts, history and physical examination are presented. A 65-year-old male patient was diagnosed with smouldering multiple myeloma, a 72-year-old male patient with chronic lymphocytic leukemia and a 42-year-old male patient with myelodysplastic syndrome. Bone marrow examination led to the diagnosis in each one of these cases. Of note is that each of the potential donors was discovered to have the same disease as the transplant recipient. In vitro clonogenic hemopoietic progenitor assays were compared to those of 20 normal volunteers. Inferior growth of hemopoietic progenitor colonies in all three was noted. In conclusion, particularly in older donors and donors with potential for familial malignancies, more screening investigations including bone marrow aspiration may be reasonable to investigate for occult hematological malignancies prior to stem cell donation. Clonogenic assays can contribute to detect hemopoietic abnormalities pre transplant. 相似文献
59.
R S Witte J Koeller T E Davis A B Benson B G Durie A Lipton J L Stock D L Citrin T P Jacobs 《Archives of internal medicine》1987,147(5):937-939
Malignancy-associated hypercalcemia is a common and recalcitrant problem. Current modes of therapy are often ineffective or prohibitively toxic. Clodronate disodium is a diphosphonate capable of inhibiting bone resorption resulting in a hypocalcemic effect. In this randomized, placebo-controlled study, we investigated the effect of hydration only (Rx-1) vs the effect of hydration plus either intravenously administered clodronate disodium, 4 mg/kg of body weight per day for three days (Rx-2) or intravenously administered clodronate disodium, 12 mg/kg of body weight given once only (Rx-3). By the third day of observation, Rx-2 produced a significant 2.8 mg/dL (0.70 mmol/L) reduction in serum calcium levels, whereas Rx-1 and Rx-3 did not produce a significant hypocalcemic effect when compared with baseline values. There were no toxicities observed. Intravenously administered clodronate appears to be an excellent agent for the acute treatment of malignancy-associated hypercalcemia. 相似文献